Tezosentan

Tezosentan

Tezosentan

Chemical compound

Tezosentan is a non-selective ETA and ETB receptor antagonist.[1] It acts as a vasodilator and was designed by Actelion as a therapy for patients with acute heart failure. However, studies showed that tezosentan did not improve dyspnea or reduce the risk of fatal or nonfatal cardiovascular events.[2]

Quick Facts Clinical data, ATC code ...

References

  1. [1]
    Urbanowicz W, Sogni P, Moreau R, Tazi KA, Barriere E, Poirel O, et al. (December 2004). "Tezosentan, an endothelin receptor antagonist, limits liver injury in endotoxin challenged cirrhotic rats". Gut. 53 (12). BMJ Publishing Group Ltd & British Society of Gastroenterology: 1844–9. doi:10.1136/gut.2003.036517. PMC 1774327. PMID 15542526.
  2. [2]
    "Tezosentan does not appear to improve symptoms for patients with acute heart failure". Medical Studies/Trials. news-medical.net. 7 Nov 2007. Retrieved 2007-11-24.


Stub icon

This drug article relating to the cardiovascular system is a stub. You can help Wikipedia by expanding it.
Share this article:

This article uses material from the Wikipedia article Tezosentan, and is written by contributors. Text is available under a CC BY-SA 4.0 International License; additional terms may apply. Images, videos and audio are available under their respective licenses.